Biomarin To Host Investor Day Today At 10:30 A.M. Eastern Time

(MENAFN- PR Newswire) NEW YORK, Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will host its Investor Day today in New York.
The event begins at 10:30 a.m. Eastern Time and can be accessed virtually here .

Led by President and Chief Executive Officer Alexander Hardy, the event will feature presentations from BioMarin's leadership team as they introduce strategic priorities that underscore BioMarin's commitment to deliver significant value creation. A question-and-answer session will follow prepared remarks.

BioMarin's Investor Day Agenda:

• BioMarin's New Corporate Strategy to Deliver Significant and Sustained Value Creation to Stakeholders
  Alexander Hardy, President and Chief Executive Officer
  
• Value Commitment: Financial Strategy to Deliver
  High Growth and
  Superior
  Returns
  Brian Mueller, Executive Vice President,
  Chief Financial Officer
  
• Innovation Strategy to Deliver Sustainable Pipeline of High Impact Medicines
  Hank Fuchs, M.D., President, Worldwide R&D
  
• Commercial Growth Strategy:
  • o
    Optimizing BioMarin's Growing and Durable
    Enzyme Therapies Business Unit
  • o
    Building Leadership in Achondroplasia to Set the Stage for Multiple New Indications
    Cristin Hubbard, Executive Vice President, Chief Commercial Officer

A link to the live webcast, replay and presentation slides will be available on BioMarin's Investor Relations website for at least 12 months at href="" rel="nofollow" biomari .

About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit
.

Contacts:
Investors	Media
Traci McCarty	Marni Kottle
BioMarin Pharmaceutical Inc.	BioMarin Pharmaceutical Inc.
(415) 455-7558	(415) 218-7111

SOURCE BioMarin Pharmaceutical Inc.

MENAFN04092024003732001241ID1108635213